Cristian Massacesi, Executive Vice President, Chief Medical Officer and Head of Development at Bristol Myers Squibb, shared a post on LinkedIn:
It was great to spend time last week at Dana-Farber Cancer Institute connecting with clinicians and researchers who are shaping the future of cancer care.
These conversations about our ongoing collaborations across stages of development are always valuable – not only to review where the science is headed, but to understand the realities of clinical practice and how we can design studies and strategies that truly make a difference for patients.
Institutions like Dana-Farber play a critical role in translating innovation into meaningful progress. The depth of expertise, commitment to rigorous clinical research, and shared focus on improving outcomes is what makes partnerships like this so important.
Thank you to the Dana-Farber team, including Toni Choueiri, Sara Tolaney, Pasi Jänne, and Paolo Tarantino, for the candid discussions and shared commitment to advancing new medicines for people living with cancer.”
Other articles about Dana-Farber on OncoDaily.